# Phase I Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile Of Lenalidomide (Revlimid®, CC-5013) With Pemetrexed In Subjects With Advanced Non-Small Cell Lung Cancer

> **NCT00179699** · PHASE1 · TERMINATED · sponsor: **Celgene Corporation** · enrollment: 40 (—)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** CC-5013
- **DRUG:** pemetrexed

## Key facts

- **NCT ID:** NCT00179699
- **Lead sponsor:** Celgene Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-09
- **Primary completion:** —
- **Final completion:** 2006-11
- **Target enrollment:** 40 (—)
- **Last updated:** 2005-11-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00179699

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00179699, "Phase I Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile Of Lenalidomide (Revlimid®, CC-5013) With Pemetrexed In Subjects With Advanced Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00179699. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*